FDA's GLP-1 Green List Is Not a Complete Supply-Chain Check

Renewed coverage of FDA's GLP-1 ingredient import system puts a familiar supplier question back in view: what does a Green List entry actually establish? The agency's October 9 revision to Import Alert 66-80 added orforglipron entries and updated the evidence manufacturers can submit for listing. Separately, 20 state attorneys general have questioned whether the system can adequately track the true source of imported ingredients. These are related supply-chain issues, but they are not the same action or the same date. [1][3][5]

The Green List is a specific import exception

Import Alert 66-80 concerns GLP-1 receptor agonist bulk drug substances, also called active pharmaceutical ingredients or APIs. Its guidance says FDA divisions may detain shipments without physical examination, except for the products and firms identified on the alert's Green List. The list concerns facilities and associated products that, based on FDA's evaluation of recent evidence, appear to comply with current good manufacturing practice requirements. That is narrower than a general endorsement of a supplier's catalog. [1]

The document also states its own legal status: it is current guidance to FDA field personnel, "does not create or confer any rights" and "does not operate to bind FDA or the public." Describing it as an import-control tool is more accurate than calling the October revision a new statute or a blanket ban. FDA's separate public explanation says the action neither stops legal imports from compliant API manufacturers nor creates new limits on legal GLP-1 compounding. [1][4]

For a clinic reading a pharmacy's sourcing materials, the practical distinction is between a specific listing and a finished prescription. A listing addresses an ingredient and its manufacturing source within this import framework. It does not itself establish that a particular finished compounded product has been reviewed or approved by FDA. The agency states that compounded drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness and quality. [1][4]

What changed in October

The alert is published with an October 9, 2026 date. Its revision note says orforglipron API was added for three manufacturers already on the Green List, with orforglipron spray-dried dispersion, a drug-product intermediate, added for another manufacturer. It also identifies new product codes and changes to the guidance on information submitted for Green List consideration. Those are the changes FDA actually describes. [1]

The note links the revision to a March 19 memorandum within FDA. It does not describe the change as a response to the state attorneys general's September letter. November 5 reporting by Grey Pepper brought the import revision and the states' criticism together, but that later coverage should not turn an October agency update into a November announcement, or create a causal connection the agency has not stated. [1][5]

The listing changes also should not be read as identifying who supplies any particular branded medicine. The alert describes manufacturers, products and import treatment. It is not a public map of every commercial purchasing relationship. A clinic should keep those questions separate rather than treating the appearance of an ingredient name as evidence of a particular supply agreement. [1]

Harbin shows why the original manufacturer matters

FDA's May 1 warning letter to Harbin Jixianglong Biotech provides a concrete example of the traceability issue. Following a November 2025 inspection, FDA said the company purchased semaglutide API from outside suppliers and repackaged and relabeled it without adequate documentation or quality-unit controls. Labels identified Harbin as the manufacturer rather than the original source, and manufacturing and retest dates were changed without appropriate supporting data. These are FDA's findings in a warning letter, not a criminal verdict. [2]

The letter identifies two batches distributed to the United States, on August 23 and October 3, 2025. Harbin had joined the Green List on September 5, so one shipment preceded its placement and the other followed it. FDA specifically described an original source facility that was not on the Green List. It expressed concern that identifying Harbin instead of the actual manufacturers "may have been an attempt to circumvent safeguards." The qualification matters: a stated concern about intent should not become an adjudicated finding of deliberate evasion. [2]

The chronology also includes an enforcement response. FDA says Harbin initiated a voluntary recall of the two batches on February 19, 2026. On February 27, FDA removed the firm from the Green List and placed it on Import Alert 66-40, concerning drugs from firms that have not met manufacturing requirements. Those actions predated both the May warning letter and the states' September appeal. The record therefore describes a traceability failure and subsequent agency action, not an unchanged listing that FDA simply left in place. [2]

A supplier's listed name and an ingredient's actual manufacturing history are different pieces of evidence.

The states' letter is a request, not a new rule

The September 17 letter, led by Alabama and signed by attorneys general from 20 states, argues that a Green List can be exploited when true source and chain of custody are not verified in real time. It cites Harbin and asks for stronger federal coordination, information sharing and attention to pharmaceutical supply-chain risks. A September 21 West Virginia announcement describes its participation in that coalition. These are statements of the officials' concerns and requested action. [3][6]

The letter does not itself amend FDA's import alert, create a new clinic obligation or establish that every listed manufacturer has committed misconduct. Nor should its broader allegations about foreign chemical networks be used to label an individual pharmacy or clinic without evidence connecting that business to the conduct. The specific FDA record supports a narrower, useful lesson: documentation should identify the actual manufacturer rather than stopping at a distributor's name. [2][3]

A useful conversation with a pharmacy

For an independent clinic, this reporting supports a sourcing conversation, not a new patient-facing promise. Ask the pharmacy to explain how it identifies the original API manufacturer, matches that source to the relevant product listing, and preserves lot-level traceability when intermediaries are involved. Ask how changes in a supplier's status are detected and how a recall would be traced to affected inventory. These are operational questions drawn from the documented failure, not a claim that FDA has imposed a new checklist on clinics. [1][2]

FDA's alert illustrates the depth of evidence behind a listing request: examples include certificates of analysis, container labels, manufacturing-site information, testing specifications, stability records and process-validation material. A certificate of analysis belongs within that larger record; it is not the whole record. [1]

What it means for a clinic: Treat Green List status as a specific, changeable import fact. Keep it separate from product approval, pharmacy qualification and the legal basis for an individual compounded prescription. The question worth asking is whether the pharmacy can explain where an ingredient was actually made and how that history remains connected to the medication it dispenses. [1][2][4]